<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20230727002559
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20230727002559" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 27 Jul 2023 04:26:00 +0000</lastbuilddate>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Troponins and Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494028/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2109. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494028/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37494028</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2109>10.1001/jamacardio.2023.2109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494028</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Eva Furenäs</dc:creator>
<dc:creator>Mikael Dellborg</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Troponins and Pregnancy</dc:title>
<dc:identifier>pmid:37494028</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2109</dc:identifier>
</item>
<item>
<title>Diversity in Clinical Trial Enrollment and Reporting-Where We Are and the Road Ahead</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2106. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37494022</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2106>10.1001/jamacardio.2023.2106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494022</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrew Farb</dc:creator>
<dc:creator>Charles J Viviano</dc:creator>
<dc:creator>Michelle E Tarver</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Diversity in Clinical Trial Enrollment and Reporting-Where We Are and the Road Ahead</dc:title>
<dc:identifier>pmid:37494022</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2106</dc:identifier>
</item>
<item>
<title>Troponins and Pregnancy-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2112. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37494021</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2112>10.1001/jamacardio.2023.2112</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494021</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Anum S Minhas</dc:creator>
<dc:creator>Elizabeth Selvin</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Troponins and Pregnancy-Reply</dc:title>
<dc:identifier>pmid:37494021</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2112</dc:identifier>
</item>
<item>
<title>Enrollment of Older Patients, Women, and Racial and Ethnic Minority Individuals in Valvular Heart Disease Clinical Trials: A Systematic Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: This review found that over the past 2 decades, women and racial and ethnic minority individuals have remained underrepresented in North American valvular heart disease clinical trials. Further work is needed to improve the reporting of race and ethnicity data and address barriers to trial enrollment for older patients, women, and racial and ethnic minority individuals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2098. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Inadequate representation of older patients, women, and racial minority individuals in cardiovascular clinical trials limits both the generalizability of trial findings and inclusivity in access to novel therapies and therapeutic strategies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To report on temporal trends in the representation of older patients, women, and racial and ethnic minority individuals in clinical trials studying treatments for valvular heart disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EVIDENCE REVIEW: All published clinical trials enrolling more than 100 adults with any valvular heart disease published between 2005 and 2020 were included after searches with PubMed and ClinicalTrials.gov. Data on age, sex, race, and ethnicity reported in the included studies were collected. Trials were assigned to 4 time periods based on the publication date, and temporal trends were analyzed in the representation of older patients, women, and racial and ethnic minority individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">FINDINGS: A total of 139 clinical trials with 51 527 participants were identified. Of these trials, 103 (74%) investigated aortic valve disease and the remainder mitral valve disease. Overall, 63 trials (45.3%) enrolled patients only in Europe, 24 (17.3%) only in North America, and 19 (13.7%) in multiple geographical regions. The weighted mean (SD) age of enrolled patients was 68.4 (11.4) years, increasing nonsignificantly from 61.9 (5.9) years in 2005-2008 to 72.8 (9.6) years in 2017-2020 (P = .09 for trend). The overall proportion of women enrolled in valvular heart disease trials was 41.1%, with no significant changes over time. Data on race and ethnicity of trial participants were reported in 13 trials (9.4%), in which trial-level representation of American Indian/Alaska Native, Asian, Black/African American, Hispanic, and Native Hawaiian/Pacific Islander patients ranged from 0.27% to 43.9%. There were no significant temporal trends noted in the enrollment of racial and ethnic minority populations. The representation of women in clinical trials was positively associated with enrollment rates of older patients and underrepresented racial and ethnic groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This review found that over the past 2 decades, women and racial and ethnic minority individuals have remained underrepresented in North American valvular heart disease clinical trials. Further work is needed to improve the reporting of race and ethnicity data and address barriers to trial enrollment for older patients, women, and racial and ethnic minority individuals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37494015</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2098>10.1001/jamacardio.2023.2098</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494015</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Kriyana P Reddy</dc:creator>
<dc:creator>Michela Faggioni</dc:creator>
<dc:creator>Lauren A Eberly</dc:creator>
<dc:creator>Rim Halaby</dc:creator>
<dc:creator>Monika Sanghavi</dc:creator>
<dc:creator>Jennifer Lewey</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Megan Coylewright</dc:creator>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:creator>Jay Giri</dc:creator>
<dc:creator>Alexander C Fanaroff</dc:creator>
<dc:creator>Ashwin S Nathan</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Enrollment of Older Patients, Women, and Racial and Ethnic Minority Individuals in Valvular Heart Disease Clinical Trials: A Systematic Review</dc:title>
<dc:identifier>pmid:37494015</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2098</dc:identifier>
</item>
<item>
<title>Association of Longer Leukocyte Telomere Length With Cardiac Size, Function, and Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this cross-sectional study, longer LTL was associated with a larger heart with better cardiac function in middle age, which could potentially explain the observed lower risk of incident HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2167. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Longer leukocyte telomere length (LTL) is associated with a lower risk of adverse cardiovascular outcomes. The extent to which variation in LTL is associated with intermediary cardiovascular phenotypes is unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the associations between LTL and a diverse set of cardiovascular imaging phenotypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a population-based cross-sectional study of UK Biobank participants recruited from 2006 to 2010. LTL was measured using a quantitative polymerase chain reaction method. Cardiovascular measurements were derived from cardiovascular magnetic resonance using machine learning. The median (IQR) duration of follow-up was 12.0 (11.3-12.7) years. The associations of LTL with imaging measurements and incident heart failure (HF) were evaluated by multivariable regression models. Genetic associations between LTL and significantly associated traits were investigated by mendelian randomization. Data were analyzed from January to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: LTL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cardiovascular imaging traits and HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 40 459 included participants, 19 529 (48.3%) were men, and the mean (SD) age was 55.1 (7.6) years. Longer LTL was independently associated with a pattern of positive cardiac remodeling (higher left ventricular mass, larger global ventricular size and volume, and higher ventricular and atrial stroke volumes) and a lower risk of incident HF (LTL fourth quartile vs first quartile: hazard ratio, 0.86; 95% CI, 0.81-0.91; P = 1.8 × 10-6). Mendelian randomization analysis suggested a potential causal association between LTL and left ventricular mass, global ventricular volume, and left ventricular stroke volume.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cross-sectional study, longer LTL was associated with a larger heart with better cardiac function in middle age, which could potentially explain the observed lower risk of incident HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37494011</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2167>10.1001/jamacardio.2023.2167</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494011</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Nay Aung</dc:creator>
<dc:creator>Qingning Wang</dc:creator>
<dc:creator>Stefan van Duijvenboden</dc:creator>
<dc:creator>Richard Burns</dc:creator>
<dc:creator>Svetlana Stoma</dc:creator>
<dc:creator>Zahra Raisi-Estabragh</dc:creator>
<dc:creator>Selda Ahmet</dc:creator>
<dc:creator>Elias Allara</dc:creator>
<dc:creator>Angela Wood</dc:creator>
<dc:creator>Emanuele Di Angelantonio</dc:creator>
<dc:creator>John Danesh</dc:creator>
<dc:creator>Patricia B Munroe</dc:creator>
<dc:creator>Alistair Young</dc:creator>
<dc:creator>Nicholas C Harvey</dc:creator>
<dc:creator>Veryan Codd</dc:creator>
<dc:creator>Christopher P Nelson</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:creator>Nilesh J Samani</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Association of Longer Leukocyte Telomere Length With Cardiac Size, Function, and Heart Failure</dc:title>
<dc:identifier>pmid:37494011</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2167</dc:identifier>
</item>
<item>
<title>Interaction of Filamin C With Actin Is Essential for Cardiac Development and Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37492967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our data strongly support the crucial role of FLNC as a bridge between actin filaments and ECM through its interactions with actin, ITGB1, γ-SAG, and other associated proteins in cardiomyocytes. Disruption of FLN-actin interaction may result in detachment of actin filaments from the extracellular matrix, ultimately impairing normal cardiac development and function. These findings also provide insights into mechanisms underlying cardiomyopathy associated with genetic variants in FLNC...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 26. doi: 10.1161/CIRCRESAHA.123.322750. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: FLNC (filamin C), a member of the FLN family predominantly expressed in striated muscles, plays a crucial role in bridging the cytoskeleton and ECM (extracellular matrix) in cardiomyocytes, thereby maintaining heart integrity and function. Although genetic variants within the N-terminal ABD (actin-binding domain) of FLNC have been identified in patients with cardiomyopathy, the precise contribution of the actin-binding capability to FLNC's function in mammalian hearts remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted in silico analysis of the 3-dimensional structure of mouse FLNC to identify key amino acid residues within the ABD that are essential for FLNC's actin-binding capacity. Subsequently, we performed coimmunoprecipitation and immunofluorescent assays to validate the in silico findings and assess the impact of these mutations on the interactions with other binding partners and the subcellular localization of FLNC. Additionally, we generated and analyzed knock-in mouse models in which the FLNC-actin interaction was completely disrupted by these mutations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our findings revealed that F93A/L98E mutations completely disrupted FLNC-actin interaction while preserving FLNC's ability to interact with other binding partners ITGB1 (β1 integrin) and γ-SAG (γ-sarcoglycan), as well as maintaining FLNC subcellular localization. Loss of FLNC-actin interaction in embryonic cardiomyocytes resulted in embryonic lethality and cardiac developmental defects, including ventricular wall malformation and reduced cardiomyocyte proliferation. Moreover, disruption of FLNC-actin interaction in adult cardiomyocytes led to severe dilated cardiomyopathy, enhanced lethality and dysregulation of key cytoskeleton components.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data strongly support the crucial role of FLNC as a bridge between actin filaments and ECM through its interactions with actin, ITGB1, γ-SAG, and other associated proteins in cardiomyocytes. Disruption of FLN-actin interaction may result in detachment of actin filaments from the extracellular matrix, ultimately impairing normal cardiac development and function. These findings also provide insights into mechanisms underlying cardiomyopathy associated with genetic variants in FLNC ABD and other regions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37492967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37492967</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322750>10.1161/CIRCRESAHA.123.322750</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37492967</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Xiaohai Zhou</dc:creator>
<dc:creator>Xi Fang</dc:creator>
<dc:creator>Sujay S Ithychanda</dc:creator>
<dc:creator>Tongbin Wu</dc:creator>
<dc:creator>Yusu Gu</dc:creator>
<dc:creator>Chao Chen</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Julius Bogomolovas</dc:creator>
<dc:creator>Jun Qin</dc:creator>
<dc:creator>Ju Chen</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Interaction of Filamin C With Actin Is Essential for Cardiac Development and Function</dc:title>
<dc:identifier>pmid:37492967</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322750</dc:identifier>
</item>
<item>
<title>T-Cell MyD88 Is a Novel Regulator of Cardiac Fibrosis Through Modulation of T-Cell Activation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37492941/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our results outline a novel intrinsic role for MyD88 in limiting T-cell activation that is central to tune down cardiac inflammation during cardiac adaptation to stress.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 26. doi: 10.1161/CIRCRESAHA.123.323030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac inflammation in heart failure is characterized by the presence of damage-associated molecular patterns, myeloid cells, and T cells. Cardiac damage-associated molecular patterns provide continuous proinflammatory signals to myeloid cells through TLRs (toll-like receptors) that converge onto the adaptor protein MyD88 (myeloid differentiation response 88). These induce activation into efficient antigen-presenting cells that activate T cells through their TCR (T-cell receptor). T-cell activation results in cardiotropism, cardiac fibroblast transformation, and maladaptive cardiac remodeling. T cells rely on TCR signaling for effector function and survival, and while they express MyD88 and damage-associated molecular pattern receptors, their role in T-cell activation and cardiac inflammation is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed transverse aortic constriction in mice lacking MyD88 in T cells and analyzed remodeling, systolic function, survival, and T-cell activation. We profiled WT versus <i>Myd88</i><sup><i>-/-</i></sup> mouse T cells at the transcript and protein level and performed several functional assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Analysis of single-cell RNA-sequencing data sets revealed that MyD88 is expressed in mouse and human cardiac T cells. MyD88 deletion in T cells resulted in increased levels of cardiac T-cell infiltration and fibrosis in response to transverse aortic constriction. We discovered that TCR-activated <i>Myd88</i><sup><i>-/-</i></sup> T cells had increased proinflammatory signaling at the transcript and protein level compared with WT, resulting in increased T-cell effector functions such as adhesion, migration across endothelial cells, and activation of cardiac fibroblast. Mechanistically, we found that MyD88 modulates T-cell activation and survival through TCR-dependent rather than TLR-dependent signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results outline a novel intrinsic role for MyD88 in limiting T-cell activation that is central to tune down cardiac inflammation during cardiac adaptation to stress.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37492941/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37492941</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323030>10.1161/CIRCRESAHA.123.323030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37492941</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Abraham L Bayer</dc:creator>
<dc:creator>Sasha Smolgovsky</dc:creator>
<dc:creator>Njabulo Ngwenyama</dc:creator>
<dc:creator>Ana Hernández-Martínez</dc:creator>
<dc:creator>Kuljeet Kaur</dc:creator>
<dc:creator>Katherine Sulka</dc:creator>
<dc:creator>Junedh Amrute</dc:creator>
<dc:creator>Mark Aronovitz</dc:creator>
<dc:creator>Kory Lavine</dc:creator>
<dc:creator>Shruti Sharma</dc:creator>
<dc:creator>Pilar Alcaide</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>T-Cell MyD88 Is a Novel Regulator of Cardiac Fibrosis Through Modulation of T-Cell Activation</dc:title>
<dc:identifier>pmid:37492941</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323030</dc:identifier>
</item>
<item>
<title>Unravelling ACS pathophysiology using intracoronary OCT and deep immunophenotyping</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37491589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Jul 25. doi: 10.1038/s41569-023-00915-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37491589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37491589</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00915-w>10.1038/s41569-023-00915-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37491589</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Harman</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Unravelling ACS pathophysiology using intracoronary OCT and deep immunophenotyping</dc:title>
<dc:identifier>pmid:37491589</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00915-w</dc:identifier>
</item>
<item>
<title>Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37490916/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>The T cells of the immune system can target tumors and clear solid cancers following tumor-infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a proteomic database to reveal the antigen specificities of persistent cancer-specific T cell receptors (TCRs) following successful TIL therapy for stage IV malignant melanoma. Remarkably, individual TCRs could target multiple different tumor types via the HLA A^(∗)02:01-restricted epitopes EAAGIGILTV, LLLGIGILVL, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Jul 19:S0092-8674(23)00696-7. doi: 10.1016/j.cell.2023.06.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The T cells of the immune system can target tumors and clear solid cancers following tumor-infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a proteomic database to reveal the antigen specificities of persistent cancer-specific T cell receptors (TCRs) following successful TIL therapy for stage IV malignant melanoma. Remarkably, individual TCRs could target multiple different tumor types via the HLA A<sup>∗</sup>02:01-restricted epitopes EAAGIGILTV, LLLGIGILVL, and NLSALGIFST from Melan A, BST2, and IMP2, respectively. Atomic structures of a TCR bound to all three antigens revealed the importance of the shared x-x-x-A/G-I/L-G-I-x-x-x recognition motif. Multi-epitope targeting allows individual T cells to attack cancer in several ways simultaneously. Such "multipronged" T cells exhibited superior recognition of cancer cells compared with conventional T cell recognition of individual epitopes, making them attractive candidates for the development of future immunotherapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37490916/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37490916</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.06.020>10.1016/j.cell.2023.06.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37490916</guid>
<pubDate>Tue, 25 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Garry Dolton</dc:creator>
<dc:creator>Cristina Rius</dc:creator>
<dc:creator>Aaron Wall</dc:creator>
<dc:creator>Barbara Szomolay</dc:creator>
<dc:creator>Valentina Bianchi</dc:creator>
<dc:creator>Sarah A E Galloway</dc:creator>
<dc:creator>Md Samiul Hasan</dc:creator>
<dc:creator>Théo Morin</dc:creator>
<dc:creator>Marine E Caillaud</dc:creator>
<dc:creator>Hannah L Thomas</dc:creator>
<dc:creator>Sarah Theaker</dc:creator>
<dc:creator>Li Rong Tan</dc:creator>
<dc:creator>Anna Fuller</dc:creator>
<dc:creator>Katie Topley</dc:creator>
<dc:creator>Mateusz Legut</dc:creator>
<dc:creator>Meriem Attaf</dc:creator>
<dc:creator>Jade R Hopkins</dc:creator>
<dc:creator>Enas Behiry</dc:creator>
<dc:creator>Joanna Zabkiewicz</dc:creator>
<dc:creator>Caroline Alvares</dc:creator>
<dc:creator>Angharad Lloyd</dc:creator>
<dc:creator>Amber Rogers</dc:creator>
<dc:creator>Peter Henley</dc:creator>
<dc:creator>Christopher Fegan</dc:creator>
<dc:creator>Oliver Ottmann</dc:creator>
<dc:creator>Stephen Man</dc:creator>
<dc:creator>Michael D Crowther</dc:creator>
<dc:creator>Marco Donia</dc:creator>
<dc:creator>Inge Marie Svane</dc:creator>
<dc:creator>David K Cole</dc:creator>
<dc:creator>Paul E Brown</dc:creator>
<dc:creator>Pierre Rizkallah</dc:creator>
<dc:creator>Andrew K Sewell</dc:creator>
<dc:date>2023-07-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy</dc:title>
<dc:identifier>pmid:37490916</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.06.020</dc:identifier>
</item>
<item>
<title>Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37489538/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We developed and externally validated a deep learning model that identifies LV systolic dysfunction from ECG images. This approach represents an automated and accessible screening strategy for LV systolic dysfunction, particularly in low-resource settings.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25. doi: 10.1161/CIRCULATIONAHA.122.062646. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Left ventricular (LV) systolic dysfunction is associated with a >;8-fold increased risk of heart failure and a 2-fold risk of premature death. The use of ECG signals in screening for LV systolic dysfunction is limited by their availability to clinicians. We developed a novel deep learning-based approach that can use ECG images for the screening of LV systolic dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using 12-lead ECGs plotted in multiple different formats, and corresponding echocardiographic data recorded within 15 days from the Yale New Haven Hospital between 2015 and 2021, we developed a convolutional neural network algorithm to detect an LV ejection fraction &lt;40%. The model was validated within clinical settings at Yale New Haven Hospital and externally on ECG images from Cedars Sinai Medical Center in Los Angeles, CA; Lake Regional Hospital in Osage Beach, MO; Memorial Hermann Southeast Hospital in Houston, TX; and Methodist Cardiology Clinic of San Antonio, TX. In addition, it was validated in the prospective Brazilian Longitudinal Study of Adult Health. Gradient-weighted class activation mapping was used to localize class-discriminating signals in ECG images.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 385 601 ECGs with paired echocardiograms were used for model development. The model demonstrated high discrimination power across various ECG image formats and calibrations in internal validation (area under receiving operation characteristics [AUROCs], 0.91; area under precision-recall curve [AUPRC], 0.55); and external sets of ECG images from Cedars Sinai (AUROC, 0.90 and AUPRC, 0.53), outpatient Yale New Haven Hospital clinics (AUROC, 0.94 and AUPRC, 0.77), Lake Regional Hospital (AUROC, 0.90 and AUPRC, 0.88), Memorial Hermann Southeast Hospital (AUROC, 0.91 and AUPRC 0.88), Methodist Cardiology Clinic (AUROC, 0.90 and AUPRC, 0.74), and Brazilian Longitudinal Study of Adult Health cohort (AUROC, 0.95 and AUPRC, 0.45). An ECG suggestive of LV systolic dysfunction portended a >;27-fold higher odds of LV systolic dysfunction on transthoracic echocardiogram (odds ratio, 27.5 [95% CI, 22.3-33.9] in the held-out set). Class-discriminative patterns localized to the anterior and anteroseptal leads (V<sub>2</sub> to V<sub>3</sub>), corresponding to the left ventricle regardless of the ECG layout. A positive ECG screen in individuals with an LV ejection fraction ≥40% at the time of initial assessment was associated with a 3.9-fold increased risk of developing incident LV systolic dysfunction in the future (hazard ratio, 3.9 [95% CI, 3.3-4.7]; median follow-up, 3.2 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We developed and externally validated a deep learning model that identifies LV systolic dysfunction from ECG images. This approach represents an automated and accessible screening strategy for LV systolic dysfunction, particularly in low-resource settings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37489538/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37489538</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062646>10.1161/CIRCULATIONAHA.122.062646</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37489538</guid>
<pubDate>Tue, 25 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Veer Sangha</dc:creator>
<dc:creator>Arash A Nargesi</dc:creator>
<dc:creator>Lovedeep S Dhingra</dc:creator>
<dc:creator>Akshay Khunte</dc:creator>
<dc:creator>Bobak J Mortazavi</dc:creator>
<dc:creator>Antônio H Ribeiro</dc:creator>
<dc:creator>Evgeniya Banina</dc:creator>
<dc:creator>Oluwaseun Adeola</dc:creator>
<dc:creator>Nadish Garg</dc:creator>
<dc:creator>Cynthia A Brandt</dc:creator>
<dc:creator>Edward J Miller</dc:creator>
<dc:creator>Antonio Luiz J Ribeiro</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Luana Giatti</dc:creator>
<dc:creator>Sandhi M Barreto</dc:creator>
<dc:creator>Murilo Foppa</dc:creator>
<dc:creator>Neal Yuan</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2023-07-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images</dc:title>
<dc:identifier>pmid:37489538</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.062646</dc:identifier>
</item>
<item>
<title>Age at Menopause, Leukocyte Telomere Length, and Coronary Artery Disease in Postmenopausal Women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37489536/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Earlier age at menopause is associated with shorter LTL, especially among women with natural menopause. Accelerated telomere shortening may contribute to the heightened cardiovascular risk associated with premature menopause.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 25. doi: 10.1161/CIRCRESAHA.123.322984. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Premature menopause is a risk factor for accelerated cardiovascular aging, but underlying mechanisms remain incompletely understood. This study investigated the role of leukocyte telomere length (LTL), a marker of cellular aging and genomic instability, in the association of premature menopause with cardiovascular disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants from the UK Biobank and Women's Health Initiative with complete reproductive history and LTL measurements were included. Primary analyses tested the association between age at menopause and LTL using multivariable-adjusted linear regression. Secondary analyses stratified women by history of gynecologic surgery. Mendelian randomization was used to infer causal relationships between LTL and age at natural menopause. Multivariable-adjusted Cox regression and mediation analyses tested the joint associations of premature menopause and LTL with incident coronary artery disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 130 254 postmenopausal women (UK Biobank: n=122 224; Women's Health Initiative: n=8030), of whom 4809 (3.7%) had experienced menopause before age 40. Earlier menopause was associated with shorter LTL (meta-analyzed ß=-0.02 SD/5 years of earlier menopause [95% CI, -0.02 to -0.01]; <i>P</i>=7.2×10<sup>-12</sup>). This association was stronger and significant in both cohorts for women with natural/spontaneous menopause (meta-analyzed ß=-0.04 SD/5 years of earlier menopause [95% CI, -0.04 to -0.03]; <i>P</i>&lt;2.2×10<sup>-16</sup>) and was independent of hormone therapy use. Mendelian randomization supported a causal association of shorter genetically predicted LTL with earlier age at natural menopause. LTL and age at menopause were independently associated with incident coronary artery disease, and mediation analyses indicated small but significant mediation effects of LTL in the association of menopausal age with coronary artery disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Earlier age at menopause is associated with shorter LTL, especially among women with natural menopause. Accelerated telomere shortening may contribute to the heightened cardiovascular risk associated with premature menopause.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37489536/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37489536</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322984>10.1161/CIRCRESAHA.123.322984</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37489536</guid>
<pubDate>Tue, 25 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Art Schuermans</dc:creator>
<dc:creator>Tetsushi Nakao</dc:creator>
<dc:creator>Md Mesbah Uddin</dc:creator>
<dc:creator>Whitney Hornsby</dc:creator>
<dc:creator>Shriie Ganesh</dc:creator>
<dc:creator>Aladdin H Shadyab</dc:creator>
<dc:creator>Simin Liu</dc:creator>
<dc:creator>Bernhard Haring</dc:creator>
<dc:creator>Chrisandra L Shufelt</dc:creator>
<dc:creator>Margaret A Taub</dc:creator>
<dc:creator>Rasika A Mathias</dc:creator>
<dc:creator>Charles Kooperberg</dc:creator>
<dc:creator>Alexander P Reiner</dc:creator>
<dc:creator>Alexander G Bick</dc:creator>
<dc:creator>JoAnn E Manson</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:date>2023-07-25</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Age at Menopause, Leukocyte Telomere Length, and Coronary Artery Disease in Postmenopausal Women</dc:title>
<dc:identifier>pmid:37489536</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322984</dc:identifier>
</item>
<item>
<title>Correction to: Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37486999/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25;148(4):e4. doi: 10.1161/CIR.0000000000001167. Epub 2023 Jul 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37486999/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37486999</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001167>10.1161/CIR.0000000000001167</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37486999</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:date>2023-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association</dc:title>
<dc:identifier>pmid:37486999</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001167</dc:identifier>
</item>
<item>
<title>Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37486998/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>SGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose and sodium in the early proximal renal tubule, but the magnitude and duration of any ensuing natriuretic or diuretic effect are the result of an interplay between the degree of upregulation of SGLT2 and sodium-hydrogen exchanger 3, the extent to which downstream compensatory tubular mechanisms are activated, and (potentially) the volume set point in individual patients. A comprehensive review and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25;148(4):354-372. doi: 10.1161/CIRCULATIONAHA.123.064346. Epub 2023 Jul 24.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">SGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose and sodium in the early proximal renal tubule, but the magnitude and duration of any ensuing natriuretic or diuretic effect are the result of an interplay between the degree of upregulation of SGLT2 and sodium-hydrogen exchanger 3, the extent to which downstream compensatory tubular mechanisms are activated, and (potentially) the volume set point in individual patients. A comprehensive review and synthesis of available studies reveals several renal response patterns with substantial variation across studies and clinical settings. However, the common observation is an absence of a large acute or chronic diuresis or natriuresis with these agents, either when given alone or combined with other diuretics. This limited response results from the fact that renal compensation to these drugs is rapid and nearly complete within a few days or weeks, preventing progressive volume losses. Nevertheless, the finding that fractional excretion of glucose and lithium (the latter being a marker of proximal sodium reabsorption) persists during long-term treatment with SGLT2 inhibitors indicates that pharmacological tolerance to the effects of these drugs at the level of the proximal tubule does not meaningfully occur. This persistent proximal tubular effect of SGLT2 inhibitors can be hypothesized to produce a durable improvement in the internal set point for volume homeostasis, which may become clinically important during times of fluid expansion. However, it is difficult to know whether a treatment-related change in the volume set point actually occurs or contributes to the effect of these drugs to reduce the risk of major heart failure events. SGLT2 inhibitors exert cardioprotective effects by a direct effect on cardiomyocytes that is independent of the presence of or binding to SGLT2 or the actions of these drugs on the proximal renal tubule. Nevertheless, changes in the volume set point mediated by SGLT2 inhibitors might potentially act cooperatively with the direct favorable molecular and cellular effects of these drugs on cardiomyocytes to mediate their benefits on the development and clinical course of heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37486998/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37486998</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10358443/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">PMC10358443</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064346>10.1161/CIRCULATIONAHA.123.064346</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37486998</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Christopher S Wilcox</dc:creator>
<dc:creator>Jeffrey M Testani</dc:creator>
<dc:date>2023-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes</dc:title>
<dc:identifier>pmid:37486998</dc:identifier>
<dc:identifier>pmc:PMC10358443</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064346</dc:identifier>
</item>
<item>
<title>FDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37486997/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25;148(4):309-311. doi: 10.1161/CIRCULATIONAHA.123.065585. Epub 2023 Jul 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37486997/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37486997</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065585>10.1161/CIRCULATIONAHA.123.065585</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37486997</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Syed Mukhtar Ahmed</dc:creator>
<dc:creator>Rabindra V Shivnaraine</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2023-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>FDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish</dc:title>
<dc:identifier>pmid:37486997</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065585</dc:identifier>
</item>
<item>
<title>Effect of Initial Treatment With a Single Pill Containing Quadruple Combination of Quarter Doses of Blood Pressure Medicines Versus Standard Dose Monotherapy in Patients With Hypertension on Ambulatory Blood Pressure Indices: Results From the QUARTET Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37486996/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25;148(4):375-377. doi: 10.1161/CIRCULATIONAHA.123.064964. Epub 2023 Jul 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37486996/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37486996</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064964>10.1161/CIRCULATIONAHA.123.064964</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37486996</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Janis M Nolde</dc:creator>
<dc:creator>Emily Atkins</dc:creator>
<dc:creator>Simone Marschner</dc:creator>
<dc:creator>Graham S Hillis</dc:creator>
<dc:creator>John Chalmers</dc:creator>
<dc:creator>Laurent Billot</dc:creator>
<dc:creator>Mark R Nelson</dc:creator>
<dc:creator>Christopher M Reid</dc:creator>
<dc:creator>Peter Hay</dc:creator>
<dc:creator>Michael Burke</dc:creator>
<dc:creator>Shirley Jansen</dc:creator>
<dc:creator>Tim Usherwood</dc:creator>
<dc:creator>Anthony Rodgers</dc:creator>
<dc:creator>Clara K Chow</dc:creator>
<dc:creator>Markus P Schlaich</dc:creator>
<dc:date>2023-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Initial Treatment With a Single Pill Containing Quadruple Combination of Quarter Doses of Blood Pressure Medicines Versus Standard Dose Monotherapy in Patients With Hypertension on Ambulatory Blood Pressure Indices: Results From the QUARTET Study</dc:title>
<dc:identifier>pmid:37486996</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064964</dc:identifier>
</item>
<item>
<title>Letter by Vázquez et al Regarding Article, "Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37486995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25;148(4):378. doi: 10.1161/CIRCULATIONAHA.122.063700. Epub 2023 Jul 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37486995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37486995</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063700>10.1161/CIRCULATIONAHA.122.063700</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37486995</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Eduardo Vázquez</dc:creator>
<dc:creator>Teresa Vázquez-Sánchez</dc:creator>
<dc:creator>Carmen Sánchez-Perales</dc:creator>
<dc:date>2023-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Vázquez et al Regarding Article, "Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:37486995</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063700</dc:identifier>
</item>
<item>
<title>Extreme Heat and Poor Air Quality: Dual Threats to Cardiovascular Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37486994/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25;148(4):324-326. doi: 10.1161/CIRCULATIONAHA.123.065572. Epub 2023 Jul 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37486994/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37486994</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065572>10.1161/CIRCULATIONAHA.123.065572</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37486994</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Sameed Ahmed M Khatana</dc:creator>
<dc:creator>Peter W Groeneveld</dc:creator>
<dc:date>2023-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Extreme Heat and Poor Air Quality: Dual Threats to Cardiovascular Health</dc:title>
<dc:identifier>pmid:37486994</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065572</dc:identifier>
</item>
<item>
<title>Extreme Temperature Events, Fine Particulate Matter, and Myocardial Infarction Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37486993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This study provides consistent evidence that exposure to both ETEs and PM(2.5) is significantly associated with an increased odds of MI mortality, especially for women and older adults, and that heat wave interacts synergistically with PM(2.5) to trigger MI deaths but cold spell does not. Our findings suggest that mitigating both ETE and PM(2.5) exposures may bring health cobenefits in preventing premature deaths from MI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25;148(4):312-323. doi: 10.1161/CIRCULATIONAHA.122.063504. Epub 2023 Jul 24.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Extreme temperature events (ETEs), including heat wave and cold spell, have been linked to myocardial infarction (MI) morbidity; however, their effects on MI mortality are less clear. Although ambient fine particulate matter (PM<sub>2.5</sub>) is suggested to act synergistically with extreme temperatures on cardiovascular mortality, it remains unknown if and how ETEs and PM<sub>2.5</sub> interact to trigger MI deaths.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020, was conducted to investigate the association of exposure to ETEs and PM<sub>2.5</sub> with MI mortality and evaluate their interactive effects. On the basis of ambient apparent temperature, multiple temperature thresholds and durations were used to build 12 ETE definitions. Daily ETEs and PM<sub>2.5</sub> exposures were assessed by extracting values from validated grid datasets at each subject's geocoded residential address. Conditional logistic regression models were applied to perform exposure-response analyses and estimate relative excess odds due to interaction, proportion attributable to interaction, and synergy index.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Under different ETE definitions, the odds ratio of MI mortality associated with heat wave and cold spell ranged from 1.18 (95% CI, 1.14-1.21) to 1.74 (1.66-1.83), and 1.04 (1.02-1.06) to 1.12 (1.07-1.18), respectively. Lag 01-day exposure to PM<sub>2.5</sub> was significantly associated with an increased odds of MI mortality, which attenuated at higher exposures. We observed a significant synergistic interaction of heat wave and PM<sub>2.5</sub> on MI mortality (relative excess odds due to interaction >;0, proportion attributable to interaction >;0, and synergy index >;1), which was higher, in general, for heat wave with greater intensities and longer durations. We estimated that up to 2.8% of the MI deaths were attributable to exposure to ETEs and PM<sub>2.5</sub> at levels exceeding the interim target 3 value (37.5 μg/m<sup>3</sup>) of World Health Organization air quality guidelines. Women and older adults were more vulnerable to ETEs and PM<sub>2.5</sub>. The interactive effects of ETEs or PM<sub>2.5</sub> on MI mortality did not vary across sex, age, or socioeconomic status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides consistent evidence that exposure to both ETEs and PM<sub>2.5</sub> is significantly associated with an increased odds of MI mortality, especially for women and older adults, and that heat wave interacts synergistically with PM<sub>2.5</sub> to trigger MI deaths but cold spell does not. Our findings suggest that mitigating both ETE and PM<sub>2.5</sub> exposures may bring health cobenefits in preventing premature deaths from MI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37486993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37486993</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063504>10.1161/CIRCULATIONAHA.122.063504</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37486993</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Ruijun Xu</dc:creator>
<dc:creator>Suli Huang</dc:creator>
<dc:creator>Chunxiang Shi</dc:creator>
<dc:creator>Rui Wang</dc:creator>
<dc:creator>Tingting Liu</dc:creator>
<dc:creator>Yingxin Li</dc:creator>
<dc:creator>Yi Zheng</dc:creator>
<dc:creator>Ziquan Lv</dc:creator>
<dc:creator>Jing Wei</dc:creator>
<dc:creator>Hong Sun</dc:creator>
<dc:creator>Yuewei Liu</dc:creator>
<dc:date>2023-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Extreme Temperature Events, Fine Particulate Matter, and Myocardial Infarction Mortality</dc:title>
<dc:identifier>pmid:37486993</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063504</dc:identifier>
</item>
<item>
<title>Exercise-Induced Chest Pain: Ischemia or Something Else</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37486992/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 25;148(4):373-374. doi: 10.1161/CIRCULATIONAHA.123.065262. Epub 2023 Jul 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37486992/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37486992</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065262>10.1161/CIRCULATIONAHA.123.065262</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37486992</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Zhao-Wei Yin</dc:creator>
<dc:creator>JiangBo Duan</dc:creator>
<dc:date>2023-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Exercise-Induced Chest Pain: Ischemia or Something Else</dc:title>
<dc:identifier>pmid:37486992</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065262</dc:identifier>
</item>
<item>
<title>The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37482673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 24:ehad429. doi: 10.1093/eurheartj/ehad429. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37482673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37482673</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad429>10.1093/eurheartj/ehad429</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37482673</guid>
<pubDate>Mon, 24 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>J Hans DeVries</dc:creator>
<dc:creator>Alar Irs</dc:creator>
<dc:creator>Hans L Hillege</dc:creator>
<dc:date>2023-07-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients</dc:title>
<dc:identifier>pmid:37482673</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad429</dc:identifier>
</item>
<item>
<title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37480922/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727002559&amp;v=2.17.9.post6+86293ac
      <description>AIM: The "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease" provides an update to and consolidates new evidence since the "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" and the corresponding "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease."</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 14:S0735-1097(23)05281-6. doi: 10.1016/j.jacc.2023.04.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease" provides an update to and consolidates new evidence since the "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" and the corresponding "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease."</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost-value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37480922/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727002559&v=2.17.9.post6+86293ac">37480922</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.003>10.1016/j.jacc.2023.04.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37480922</guid>
<pubDate>Sat, 22 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Writing Committee Members</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>L Kristin Newby</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Vera Bittner</dc:creator>
<dc:creator>LaPrincess C Brewer</dc:creator>
<dc:creator>Susan Halli Demeter</dc:creator>
<dc:creator>Dave L Dixon</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Beverly Hess</dc:creator>
<dc:creator>Heather M Johnson</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Dhaval Kolte</dc:creator>
<dc:creator>Dharam J Kumbhani</dc:creator>
<dc:creator>Jim LoFaso</dc:creator>
<dc:creator>Dhruv Mahtta</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>Margo Minissian</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:creator>Amit R Patel</dc:creator>
<dc:creator>Mariann R Piano</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:creator>Amy W Talbot</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Randal J Thomas</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>Barbara Wiggins</dc:creator>
<dc:creator>Marlene S Williams</dc:creator>
<dc:date>2023-07-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:37480922</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.003</dc:identifier>
</item>





























</channel>
</rss>